Corentec Co., Ltd. Overview
Corentec is Korea's first dedicated manufacturer of artificial joints and its domestic share leader in total hip arthroplasty. Its core portfolio is primary and revision hip and knee replacement systems: BENCOX/BENFIX hips, and LOSPA and EXULT knees. Shoulder (CORALIS), spinal fixation (LOSPA IS), sports-medicine and trauma lines complement them.
The company differentiates on proprietary implant surface technologies, MAO (micro-arc oxidation) and DMT coatings. It combines a cost-competitive Korean manufacturing base with regulatory clearances in the US (FDA), Japan (MHLW), India (CDSCO), Mexico, Brazil and about 20 export markets.
The group also holds a 51.2% stake in Sun Healthcare International. That subsidiary owns a US ambulatory surgery centre in Huntington Beach, California, and runs Korean corporate health-screening and medical-device distribution businesses.
At about KRW 100bn of revenue, Corentec is a sub-scale niche challenger to the global "big four" orthopaedic majors. Its equity story rests on export growth, profitability normalisation after the 2024 trough, and deleveraging. Governance volatility, including four CEO changes since 2023, is the main overhang.
What the company does
Corentec designs, manufactures and sells orthopaedic implants and the associated surgical instruments. Joint reconstruction is the core: hip and knee implants account for the large majority of revenue.
Product lines (corentec.com product menu; Morningstar; Simply Wall St):
-
Hip: BENCOX, BENFIX
-
Knee: LOSPA, EXULT
-
Shoulder: CORALIS
-
Spine: LOSPA IS
-
Sports medicine: CorLock suture anchor
-
Trauma: LCfit HTO plate, Optirad volar plate
Manufacturing is concentrated at the Cheonan plant in South Chungcheong Province.
Reported business segments
| Segment (as reported) | Share of Q2 2026 revenue | Contents |
|---|---|---|
| Artificial joints (인공관절) | 80% | Corentec parent; hip, knee, shoulder, spine, sports medicine, trauma implants and instruments; Korea and exports including the US |
| Medical-device wholesale (의료기기도매) | 16% | Distribution activity, attributed to subsidiary Sun Healthcare International, whose business model includes medical-device distribution (TheVC) |
| Information services & ambulatory surgery centre (정보이용 및 외래수술센터) | 4% | Sun Healthcare's B2B health-screening platform and the Sun Surgery Center Huntington ASC in California |
Revenue mix by segment, Q2 2026 (Butler, from the H1 2026 report):
Revenue and business model
| Model element | Characterisation |
|---|---|
| Product vs service | Predominantly product sales of implants (about 80%), plus distribution (about 16%) and services (about 4%: health-screening intermediation, ASC procedures) |
| Subscription / licensing | None material disclosed |
| Pricing | In Korea, implant pricing is governed by National Health Insurance reimbursement ceilings (structural industry feature; company-specific price lists not disclosed). Export pricing is set with distributors, e.g. contract unit prices under the Biortotec (Mexico) supply agreement (SmartToday, Mar 2023) |
| Channel | Domestic: hospital and dealer (대리점) networks. Exports: exclusive or regional distributors (Mexico: Biortotec; India: three regional distributors). US: subsidiary Corentec America (company releases; Medigate 2022) |
| Value-chain position | Vertically integrated designer and manufacturer (design, machining, surface treatment, sterilisation and packaging at Cheonan). Downstream exposure through the ASC, the only US ASC owned by a joint-implant maker, per the company in 2022 (Dealsite, Jul 2022) |
Customers and end-markets
Customers: orthopaedic surgeons, hospitals (tertiary to secondary), ASCs and national distributors.
End-markets: primary and revision total hip and knee arthroplasty, shoulder arthroplasty, spinal fusion, sports-medicine soft-tissue repair, and trauma fixation.
Demand driver: population ageing in Korea and export markets (Korean Investing.com commentary, 2020; company IR, 2018).
Company self-description vs independent characterisation
Company description. In its FY2025 results release (10 Feb 2026), the company calls itself Korea's first specialist artificial-joint manufacturer since its founding in 2000. It says it develops hip, knee and spinal-fixation devices, and that FY2025 marked a qualitative change in its earnings structure.
Independent characterisation. Corentec is a single-plant, export-leveraged orthopaedic implant maker with a defensible Korean hip franchise. The franchise is reported as the domestic hip share leader for seven consecutive years as of 2023 (KED Global, Jul 2023), but the company is No. 3 in Korean knees (Edaily, 2023). Exports run at about 40% of revenue, with the US the largest export market, at roughly KRW 14bn in 2023 (Pharm Edaily, 2024).
From 2022 to 2024 management tried to become a "comprehensive healthcare company":
-
dental prosthetics licensing from RODO Medical;
-
the Sun Healthcare ASC and screening business;
-
Woosung Pharmaceutical (generic injectables).
The pharmaceutical leg was reversed in March 2025, and the China subsidiary was liquidated in 2024. Since then the company has refocused on the implant core under a profitability and deleveraging agenda.
Strategy
Stated strategic themes (company releases 2025–2026)
-
Global market expansion. US, Latin America and Southeast Asia are the priority regions (Q1 2026 release).
-
Product competitiveness. Portfolio diversification and advanced surface-treatment technology (Q1 2026 release; Nov 2025 release).
-
Profitability and cost efficiency. The company frames FY2025 as a structural earnings turnaround that should support a stable profit base (FY2025 release).
-
Partnership-led distribution. Exhibitions (JOA Tokyo, WHX Miami, SBOT Brazil, GHE Riyadh) and distributor MOUs (Nov 2025 release).
Initiatives in the last 24 months
| Date | Initiative | Detail / target | Source |
|---|---|---|---|
| H2 2024 | China exit | Liquidation of Corentec China to concentrate on the US | Dailymedi, 2024 |
| 2,024 | Organisational reset | Dissolution of Future Strategy and New Growth offices created under CEO Kang | Dailymedi, 2024 |
| Mar 2025 | Portfolio pruning | Woosung Pharmaceutical sold for KRW 10bn | Medigate, Mar 2025 |
| Apr 2025 | US knee line extension | EXULT UCR launch; USD 6.05M (2025) → 7.86M (2026) → USD 10M+ (2027) expectation, about 30%+ annual growth | Corentec/Yakup, Apr 2025 |
| May 2025 | FY2025 joint revenue target | KRW 77.8bn (+20%) | Corentec/BioTimes, May 2025 |
| 2,025 | Deleveraging | Bond repayments of KRW 28.9bn; net debt cut to KRW 8.5bn | Valueline |
| Oct–Nov 2025 | Market development | GHE Riyadh; Biortotec USD 15M three-year MOU (Mexico) | Corentec, Nov 2025 |
| Nov 2025 | IP | Two new knee patent filings (universal tibial implant; femoral implant holder); 96 patents held | Corentec, Nov 2025 |
| 2024 (national R&D) | Technology bets | 3D printing, artificial ankle, clinician-needs customisation | TheVC |
| Dec 2025 | Leadership | Medtech-industry CEO (Hyun) appointed, after a battery-industry quality executive (Koo) | Dealsite; Etoday |
Medium-term guidance. No formal consolidated guidance for FY2026 or beyond was found. The only quantitative management targets retrieved are the EXULT UCR US sales trajectory and the FY2025 joint-segment target of KRW 77.8bn. Achievement of the latter was not disclosed separately.
ESG commitments. None disclosed beyond an ethics-management (윤리경영) policy page on the corporate website.
Products & Services
Pricing is not publicly disclosed for any product. Korean reimbursement-based pricing applies domestically.
Artificial joints — Hip
| Product | Description / capabilities | Target customer | Regulatory / launch notes | Source |
|---|---|---|---|---|
| BENCOX Hip System | Flagship hip; the line behind domestic hip share leadership | Arthroplasty surgeons, Korea and export | Korea; US; Japan MHLW approval Jul 2023; India CDSCO May 2022; Mexico | KED Global 2023; Medigate 2022 |
| BENFIX Hip System | Second hip platform | Same | Korea; India CDSCO 2022 | Medigate 2022; corentec.com |
| Mirabo Z Cup | Acetabular cup with DMT coating | Same | Mexico launch prepared in 2023 | SmartToday, Mar 2023 |
| Bipolar hip | Hemiarthroplasty option | Fracture and hemi cases | Offered in the US by Corentec America | Becker's Spine; ODT |
| Hip portfolio breadth | Eight hip product types | — | As of 2023 | Pharm Edaily, Apr 2023 |
Core technology: MAO (micro-arc oxidation) surface treatment, designed to strengthen bone–implant bonding in cementless fixation (Pharm Edaily, 2023; AsiaToday, 2010).
Artificial joints — Knee
| Product | Description / capabilities | Regulatory / launch notes | Source |
|---|---|---|---|
| LOSPA TKR System (Primary & Revision) | Total knee system with primary and revision options | Korea; India CDSCO 2022; Mexico | Medigate 2022; SmartToday 2023 |
| LOSPA II Knee System | Next-generation LOSPA | US FDA clearance (2019) | Edaily, 2019 |
| EXULT Knee System | Total knee with four tibial-insert options: CR (cruciate retaining), PS (posterior stabilised), CPS (constrained PS) and UCR (ultra-congruent and cruciate retaining) | UCR FDA clearance Apr 2025; US launch Apr 2025 | Corentec/Yakup, Apr 2025 |
| EXULT UCR insert | One insert usable whether the surgeon resects or retains the PCL | Company revenue expectations: about USD 6.05M (2025), 7.86M (2026), 10M+ (2027) | Corentec, Apr–May 2025 |
Shoulder, spine, sports medicine, trauma, other
| Line | Product | Notes | Source |
|---|---|---|---|
| Shoulder | CORALIS Total & Reverse Shoulder System | India CDSCO 2022; US clearance in process (2024) | Medigate 2022; Pharm Edaily 2024 |
| Spine | LOSPA IS spinal (pedicle-screw) system | FDA cleared; supplied to Mexico | Pharm Edaily 2024; SmartToday 2023 |
| Sports medicine | CorLock Suture Anchor | Listed on company product menu | corentec.com 2026 |
| Trauma | LCfit HTO plate system; Optirad volar plate system | High tibial osteotomy and distal radius plates | Simply Wall St profile |
| Ankle | Total ankle replacement | Under MFDS (Korea) review in 2023; national R&D project in 2024; commercial status not confirmed | Pharm Edaily 2023; TheVC |
| Bone substitutes | Bone-substitute products | Listed by GlobalData/CB Insights profile; details not disclosed | CB Insights |
| Dental | RODO Medical cement-free implant prosthetics | Korean exclusive distribution plus technology transfer (2022); current commercial scale not disclosed | Etoday, Mar 2022 |
| Instruments | Surgical instrument sets | Sold or loaned with implants; US instruments also sold | ODT |
Services (subsidiary)
| Service | Description | Scale | Source |
|---|---|---|---|
| Corporate health-screening platform | Customised screening, vaccination and psychological counselling for employees via about 600 partner hospitals | About 111 corporate clients and 600k people per year (2022); 61 companies and about 220k people (2023 figure) | Dealsite 2022; Pharm Edaily 2023 |
| Sun Surgery Center Huntington (US ASC) | Same-day joint-replacement surgery centre; discharge in 2–24 hours | 700+ surgeries and procedures per year (2022) | Dealsite, Jul 2022 |
| Medical-device distribution | Wholesale distribution (about 16% of Q2 2026 group revenue) | — | Butler; TheVC |
Financial Narrative
Income statement
Sources: Butler (revenue, OP, net income FY2021–FY2025, as reported), FnGuide (OP margins) and company release (FY2025 OP KRW 9.02bn). FY2024 is shown as originally reported.
FY2025 D&A of KRW 5.42bn is PP&E depreciation of 4.64 plus intangible amortisation of 0.78 (Valueline cash-flow statement). EBITDA is OP plus D&A.
Corentec pays no dividend (Stockopedia).
FY2024 restated base. The company states FY2025 revenue grew 17.3% and OP grew 167.2%. That implies a restated FY2024 (excluding Woosung) of about KRW 85.6bn revenue and about KRW 3.4bn OP (Corentec release, 10 Feb 2026; arithmetic derived).
Revenue CAGR FY2021–FY2025 (as reported): about 22.5%. It is heavily inflated by the 2022–2023 acquisitions.
Commentary.
2022–2023: Revenue roughly doubled from KRW 44.6bn to 92.0bn. Drivers were organic export growth (SE Asia and Latin America up 327.7% YoY in Q2 2022; US up 33.1%; Edaily Aug 2022) and the consolidation of Sun Healthcare (H2 2022) and Woosung (from May 2023). Operating margin held at 7.7–9.1%.
2024 trough: Revenue was flat at KRW 93.7bn, OP fell 45% to KRW 3.9bn, and the company booked a net loss of KRW 1.3bn. Contributing factors in the record: the cost of the "comprehensive healthcare" build-out under CEO Kang (dedicated strategy units later dissolved), the China business difficulties that led to liquidation, interest on about KRW 51bn of gross debt, and leadership disruption, with the CEO seat vacant for about three months in 2024 (Dailymedi; Daum/ChosunBiz; News1).
2025 inflection: OP rebounded to KRW 9.0bn (9.0% margin) on implant growth and cost efficiencies. The parent alone posted Q1 2025 OP up 366% YoY to KRW 1.65bn on revenue of KRW 18.0bn (+19%) (Corentec/BioTimes, May 2025). Net income returned to KRW 7.0bn, partly helped by the Woosung disposal.
1H 2026: - Revenue was KRW 50.4bn (Q1 24.6 + Q2 25.8), about +9% YoY.
-
Consolidated OP was KRW 2.35bn (Q1 0.89 + Q2 1.46), below the prior year's pace.
-
Management attributed the Q1 weakness to consolidated subsidiaries and said the parent's core business kept growing (company/CB Insights news, May 2026). This shows the subsidiaries are now a drag on group margin.
Balance sheet
Source: Valueline/DataHero consolidated statements.
Definitions: total financial debt is short-term borrowings + short-term bonds + current portion of LT debt + LT borrowings + CBs, excluding lease and other financial liabilities. Net debt is that debt minus cash and short-term financial assets. Working capital is current assets minus current liabilities.
Commentary.
Deleveraging in 2025: Gross debt fell from KRW 51.1bn to 29.3bn and net debt from 31.8bn to 8.5bn. Bond repayments of KRW 28.9bn in FY2025 (Valueline cash-flow statement) retired most of the 8th and 9th CBs.
Funding sources: The deleveraging was funded by Woosung sale proceeds (KRW 9bn cash plus a KRW 1bn CB; News1) and by operating cash flow, which rose mainly through inventory liquidation: inventories fell from 45.2 to 32.6.
Equity restructuring: Retained earnings swung from a KRW 46.3bn deficit (FY2024) to a KRW 10.1bn surplus (FY2025), while capital surplus fell from KRW 111.1bn to 61.2bn. The pattern is consistent with share premium being used to eliminate accumulated losses. That is an analytical inference; the mechanics should be confirmed in the FY2025 business report.
H1 2026: Share count rose from 12.79M to 13.41M, and share capital and share premium rose. This is consistent with conversion of remaining CBs (inference).
Receivables quality: Trade receivables of KRW 42.1bn on revenue of KRW 100.4bn imply about 153 days of sales outstanding (FY2025), long even for the Korean dealer-and-hospital channel.
Cash flow
Source: Valueline/DataHero, trailing-twelve-month values at each fiscal year-end.
Valueline's own FCF metric reads KRW 20.58bn for FY2025 and 13.22bn for TTM Jun 2026. Corentec pays no ordinary dividend, so the KRW 0.43bn of dividends paid is assumed to go to subsidiary minority holders (inference).
Commentary. FY2025 OCF of KRW 26.5bn was about 2.9× operating income, flattered by an inventory release of KRW 11.0bn. Normalised OCF looks closer to KRW 15–20bn; TTM Jun 2026 was 20.7bn. Maintenance capex is light at about KRW 3–4bn a year, roughly 3–4% of revenue. Construction-in-progress of KRW 7.5–9.3bn (FY2023 to H1 2026) suggests ongoing facility work.
Ratios
Notes:
-
FY2025 interest expense was KRW 3.88bn (Valueline). TTM Jun 2026 interest coverage improves to about 3.9× (OP 9.23 / interest 2.35).
-
Valueline shows current ROE of 8.09% (Oct 2026).
Commentary. Every leverage and liquidity metric improved in FY2025. Return metrics are only now recovering to high single digits. Working-capital intensity is the structural weakness: about 150 days of receivables plus more than 120 days of inventory measured against sales, typical of implant makers that consign instrument and implant sets. It ties up roughly KRW 75bn, close to the company's entire market capitalisation.
Quarterly run-rate
Sources: Google Finance (DART-derived); company releases; Edaily; ChickStock (DART). Q1 2025 is from the company release.
Commentary. Earnings are back-half weighted: Q3–Q4 2025 delivered 76% of FY2025 OP. 1H 2026 OP of KRW 2.35bn compares with KRW 2.41bn in 1H 2025. Repeating FY2025 OP of KRW 9.0bn therefore needs a second half similar to H2 2025. The Q2 2026 consolidated net profit of KRW 1.12bn was described as a turnaround from a loss (Edaily, Jul 2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Activity | Status |
|---|---|---|---|
Corentec Co., Ltd. | Parent (listed) | Orthopaedic implant R&D, manufacturing and sales | Active |
Corentec America Inc. | Wholly owned subsidiary | US distribution of hip, knee and spine implants and instruments | Active (corentec-usa.com) |
Sun Healthcare International Co., Ltd. (선헬스케어인터내셔널) | 51.2% subsidiary since Jul 2022 | B2B health-screening services, medical-device distribution, US ASC ownership | Active; CEO Lee Kyu-eun; about 35 staff (TheVC, Jun 2026) |
Sun Surgery Center Huntington | Held via Sun Healthcare International | Outpatient joint-replacement ASC, Huntington Beach, CA; 700+ surgeries and procedures per year at acquisition | Active (Dealsite, Jul 2022) |
Corentec China | Subsidiary established 2014 | China sales | In liquidation since 2024 (Dailymedi) |
Japan branch office | Branch | Japan market entry and surgeon network | Established before 2023 (KED Global) |
Woosung Pharmaceutical | 80% subsidiary May 2023 – Mar 2025 | Injectable generics (acetaminophen IV infusions) | Divested to Sillajen, Mar 2025 |
Segment share of revenue (%)
| Segment share of revenue (%) | Q2 2026 |
|---|---|
Artificial joints | 80 |
Medical-device wholesale | 16 |
Info services and ASC | 4 |
Implied segment revenue (KRW Bn)
| Implied segment revenue (KRW Bn) | Q2 2026 |
|---|---|
Artificial joints | 20.6 |
Medical-device wholesale | 4.1 |
Info services and ASC | 1.0 |
Data Point Details
| Data point | Value | Source |
|---|---|---|
Hip + knee share of revenue, Q1 2023 | Hip KRW 6.4bn (38.8%), knee KRW 7.6bn (46.3%), together 85.1% as presented | Pharm Edaily, Apr 2023 |
Artificial-joint segment revenue guidance FY2025 | KRW 77.8bn (+20% YoY) | Corentec/BioTimes, May 2025 |
Artificial joints' share of revenue at Mar 2023 | More than 85% | SmartToday, Mar 2023 |
Woosung Pharmaceutical scale at divestment | About KRW 8bn revenue and KRW 1.2bn net profit per year | News1, Mar 2025 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 44.6 | 63.9 | 92.0 | 93.7 | 100.4 |
Revenue growth YoY (%) | — | 43.3 | 44.0 | 1.8 | 7.2 |
Operating income (KRW Bn) | 3.8 | 5.8 | 7.1 | 3.9 | 9.0 |
Operating margin (%) | 8.5 | 9.1 | 7.7 | 4.2 | 9.0 |
Net income incl. NCI (KRW Bn) | 0.8 | 2.7 | 5.1 | -1.3 | 7.0 |
Net margin (%) | 1.8 | 4.2 | 5.5 | -1.4 | 6.9 |
D&A (KRW Bn) | — | — | — | — | 5.4 |
EBITDA (KRW Bn) | — | — | — | — | 14.4 |
EBITDA margin (%) | — | — | — | — | 14.4 |
EPS basic (KRW) | — | — | — | -193 | — |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 171.8 | 187.1 | 186.3 | 171.9 | 165.1 |
Current assets (KRW Bn) | 114.2 | 115.5 | 116.6 | 111.9 | 104.9 |
Cash and equivalents (KRW Bn) | 15.7 | 17.1 | 17.2 | 17.8 | 23.1 |
Short-term financial assets (KRW Bn) | 5.3 | 6.8 | 2.1 | 3.0 | 2.9 |
Trade receivables (KRW Bn) | 31.4 | 40.4 | 38.1 | 42.1 | 39.2 |
Inventories (KRW Bn) | 22.5 | 35.0 | 45.2 | 32.6 | 35.5 |
PP&E (KRW Bn) | 37.2 | 44.7 | 45.3 | 38.6 | 37.6 |
Goodwill (KRW Bn) | 3.8 | 4.2 | 4.2 | 3.8 | 3.8 |
Intangibles incl. goodwill (KRW Bn) | 9.8 | 16.2 | 13.8 | 8.8 | 8.8 |
Short-term borrowings (KRW Bn) | 13.4 | 15.6 | 21.4 | 18.4 | 18.9 |
Short-term bonds (KRW Bn) | 0.0 | 0.0 | 23.7 | 4.8 | 0.0 |
Current portion of LT debt incl. bonds (KRW Bn) | 14.0 | 25.2 | 1.3 | 1.6 | 8.8 |
Long-term borrowings (KRW Bn) | 5.7 | 1.4 | 4.7 | 4.5 | 1.5 |
Convertible bonds, non-current (KRW Bn) | 11.7 | 0.0 | 0.0 | 0.0 | 0.0 |
Total financial debt (KRW Bn) | 44.8 | 42.1 | 51.1 | 29.3 | 29.3 |
Net debt (KRW Bn) | 23.8 | 18.2 | 31.8 | 8.5 | 3.3 |
Total liabilities (KRW Bn) | 96.6 | 101.0 | 101.8 | 82.8 | 71.0 |
Total equity (KRW Bn) | 75.3 | 86.1 | 84.5 | 89.2 | 94.1 |
Equity attributable to owners (KRW Bn) | 65.7 | 73.8 | 72.0 | 78.4 | 83.2 |
Non-controlling interests (KRW Bn) | 9.5 | 12.4 | 12.5 | 10.8 | 10.9 |
Working capital (KRW Bn) | 48.0 | 22.1 | 29.0 | 42.3 | 44.0 |
Book value per share (KRW) | 5,069 | 5,514 | 5,368 | 5,844 | 6,205 |
Cash Flow
| Metric | FY2025 | TTM Jun 2026 |
|---|---|---|
Operating cash flow (KRW Bn) | 26.45 | 20.65 |
of which: decrease in inventories (KRW Bn) | 10.97 | 4.12 |
Capex, PP&E (KRW Bn) | 3.15 | 3.28 |
Capex, intangibles (KRW Bn) | 0.44 | 0.96 |
Free cash flow, OCF minus capex (KRW Bn) | 22.86 | 16.41 |
Dividends paid (KRW Bn) | 0.43 | — |
Share buybacks (KRW Bn) | 0.00 | 0.00 |
Bond repayments (KRW Bn) | 28.91 | 28.35 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE, net income / average total equity (%) | — | 6.3 | -1.5 | 8.1 |
ROA, net income / average total assets (%) | — | 2.8 | -0.7 | 3.9 |
Current ratio (x) | 1.72 | 1.24 | 1.33 | 1.61 |
Debt / equity (x) | 0.60 | 0.49 | 0.60 | 0.33 |
Liabilities / equity (%) | 128 | 117 | 121 | 93 |
Net debt / EBITDA (x) | — | — | — | 0.59 |
Interest coverage, OP / interest expense (x) | — | — | — | 2.3 |
Asset turnover (x) | — | 0.51 | 0.50 | 0.56 |
DSO, trade receivables / revenue × 365 (days) | 180 | 160 | 149 | 153 |
Inventory / revenue × 365 (days) | 128 | 139 | 176 | 119 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 22.6 | 23.4 | 25.8 | 28.6 | 24.6 | 25.8 |
Operating income (KRW Bn) | 1.0 | 1.4 | 3.7 | 3.2 | 0.9 | 1.5 |
Operating margin (%) | 4.6 | 5.8 | 14.2 | 11.3 | 3.6 | 5.7 |
R&D expense (KRW Bn) | — | 0.98 | 0.91 | 0.78 | 1.01 | — |
SG&A (KRW Bn) | — | 9.02 | 8.18 | 10.04 | 9.24 | — |
Gross margin (%) | — | 51.3 | 53.2 | 52.5 | 50.3 | — |
Net income (KRW Bn) | 2.7 | — | — | — | — | 1.1 |
Revenue by Region and Revenue by Region (%)
| Region / market metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
US revenue (KRW Bn, approximate per company) | 10.0 | 14.0 | — |
Export share of revenue (%, approximate) | — | — | 40 |
Geography Overview
| Geography | Disclosed facts | Trend assessment |
|---|---|---|
Korea | Hip share leader for seven straight years (as of 2023); No. 3 in knees | Stable, reimbursement-priced core |
United States | FDA-cleared hip (2011), LOSPA II knee (2019), EXULT UCR (2025), spine; US revenue about KRW 14bn (2023); company targets UCR sales of USD 6.05M (2025) and 7.86M (2026); group owns a California ASC | Fastest-growing large market per company commentary; +33.1% YoY in Q2 2022 |
Mexico / Latin America | Entered 2017; company claims No. 2 share in Mexico after J&J; about USD 10M three-year supply contract (2023–2025); USD 15M MOU planned Nov 2025; Argentina active; Brazil approval targeted 2023; attended SBOT 2025 (Brazil) | Largest non-US export market per company; growing |
Southeast Asia | Thailand and Indonesia among about 20 export countries | +327.7% YoY in Q2 2022 (with Latin America) |
Japan | BENCOX hip MHLW approval (Jul 2023); branch office; JOA 2025 participation | Early-stage; Japan is about 50% of the APAC joint market per the company |
India | CDSCO approvals (May 2022); three regional distributors | Early-stage |
Middle East | Global Health Exhibition, Riyadh (Oct 2025) | Business development only |
China | CFDA knee approval (2013); subsidiary founded 2014 | Exited; liquidation decided 2024 |
Russia, Australia, Brazil | Named as expansion markets in 2022–2023 | Status not disclosed |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 10,800 | 11,840 | 5,110 | 6,700 |
Year-end market cap (KRW Bn) | 133.4 | 151.0 | 65.3 | 85.7 |
Book value per share (KRW) | 5,069 | 5,514 | 5,368 | 5,844 |
Price / book (x) | 2.13 | 2.15 | 0.95 | 1.15 |
Shares outstanding (M) | 12.35 | 12.76 | 12.79 | 12.79 |
Valuation Multiples
| Multiple | Corentec | Basis |
|---|---|---|
P/E (TTM) | 10.7× | Valueline |
P/B | 0.87× | Valueline (BPS ₩6,205, Jun 2026) |
EV / EBITDA (TTM) | ≈6.0× | EV ≈ KRW 86.2bn (market cap 72.0 + debt 29.3 − cash and short-term financial assets 26.0 + NCI 10.9) / TTM EBITDA ≈ 14.4 |
EV / Sales (TTM) | ≈0.82× | TTM revenue KRW 104.8bn |
ROE | 8.1% | Valueline |
Dividend yield | 0% | No dividend |
Change by Period
| Period | Change | Basis |
|---|---|---|
Year to date 2026 | -17.9% | ₩6,700 (31 Dec 2025) → ₩5,500 |
Since end-2023 (about 2.8 years) | -53.5% | ₩11,840 → ₩5,500 |
Since IPO (Mar 2013) | -65.6% | ₩16,000 offer → ₩5,500 |
52-week range (as of Jul–Aug 2026) | ₩3,385 – ₩7,440 | Google Finance; Investing.com |
Intra-2026 low point | ₩4,150 at 30 Jun 2026 | Valueline |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None; no sell-side coverage found (StockHub reports 0 reports). The Korea IR Council research centre published sponsored-style estimates in 2023: FY2023E revenue KRW 88.5bn and OP KRW 6.9bn (Pharm Edaily, Apr 2023) |
Dividend history and policy | No dividends paid; FY2025 elimination of the accumulated deficit (see §6.2) is a precondition for future distributions, but no policy has been announced |
Buybacks | No company buyback programme. Insider open-market purchases by the Sun brothers in Dec 2021 – Feb 2022 (17,279 shares) and Sep 2022 (about KRW 300M) (Asia Economy; Bizwatch) |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Debt maturity profile (H1 2026) | Short-term borrowings KRW 18.9bn; current portion of LT debt KRW 8.8bn (of which bonds 4.9, LT loans 3.6); LT borrowings KRW 1.5bn. About 95% of financial debt is current. Bank lines are typically rolled; the 9th CB's final maturity is 10 Nov 2026 |
CB history | 2016 KRW 20bn (repaid early 2019 after default); 8th KRW 15bn (Dec 2020); 9th KRW 20bn (Nov 2021, conversion price ₩14,534); bond repayments of KRW 28.9bn in FY2025 |
Analyst Conclusions
Guidance and consensus
Management guidance: No formal FY2026 consolidated guidance found. Product-level aspiration: EXULT UCR US sales of about USD 7.86M in 2026 and USD 10M+ in 2027.
Consensus: None; no sell-side coverage.
Run-rate: 1H 2026 revenue of KRW 50.4bn (+9% YoY) points to FY2026 revenue of about KRW 105–110bn if H2 follows the 2025 seasonality. This is analyst extrapolation, not a forecast from the company.
Bull case
-
Normalised earnings power is higher than the 1H run-rate. H2 2025 OP of KRW 6.9bn (12.7% margin) shows what the implant core plus seasonal strength can deliver. Applying a 12% margin to about KRW 108bn of revenue would give about KRW 13bn of OP, roughly 5× EV.
-
Balance-sheet repair unlocks optionality. Net debt fell from KRW 31.8bn to 3.3bn in 18 months and the accumulated deficit was cleared. The stock trades at 0.87× book with an 8% ROE, so modest ROE gains or a first dividend could re-rate it.
-
Export levers are already funded. FDA (EXULT UCR), MHLW (BENCOX) and CDSCO approvals, the Biortotec USD 15M MOU and an experienced medtech CEO give multiple growth paths without new capital.
Bear case
-
Governance instability destroys execution. Four CEO transitions since 2023 and repeated strategy reversals (pharma, China, dental) suggest strategy follows the controlling family rather than the CEO. CEO Hyun may not complete his term either.
-
Structural competitive disadvantage. Without robotics and with about KRW 4bn of annual R&D, Corentec risks becoming a price-taker in the US against Zimmer Biomet (USD 8.2bn), Stryker (USD 9.5bn ortho) and Smith+Nephew. US UCR targets of USD 6–10M are small in absolute terms.
-
Quality of earnings and working capital. FY2025 OCF was flattered by an inventory release of KRW 11.0bn. Receivables of about 150 days persist, and 1H 2026 OP (KRW 2.35bn) is no higher than 1H 2025. Subsidiaries are now diluting margins, and about 95% of debt is short-dated.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Nov 2026 | Q3 2026 results; test of H2 seasonal margin recovery (Q3 2025 OP margin was 14.2%) |
| 10 Nov 2026 | 9th CB final maturity; watch for residual conversions or refinancing |
| Q4 2026 – Q1 2027 | First full-year strategy articulation under CEO Hyun; any formal medium-term targets |
| Feb – Mar 2027 | FY2026 preliminary results and business report; segment profitability; any dividend proposal at the 2027 AGM |
| Ongoing | EXULT UCR US sales against USD 7.86M (2026); Biortotec MOU conversion into binding orders; Japan and India first meaningful revenue |
| Ongoing | Strategic review of Sun Healthcare International (non-core, margin-dilutive) |
| Ongoing | Insider transactions (three reports in Jun 2026) and changes in share pledges |
Analyst verdict
Corentec in late 2026 is a recovering, de-risked but still under-managed small-cap orthopaedic franchise.
Financial repair. The 2025 results mark a real inflection. Revenue crossed KRW 100bn for the first time, operating profit more than doubled to KRW 9.0bn, and net debt was cut to near zero by mid-2026. The balance-sheet crises of 2019 and 2024 have been neutralised: the convertible-bond default, the heavy short-term bond load and the KRW 51bn gross debt peak. At about 0.87× book, about 6× TTM EV/EBITDA and about 10.7× earnings, the market is not paying for the recovery.
Why the discount persists. The discount reflects three unresolved questions.
-
Governance. No professional CEO has completed a term since 2023, and the controlling family's priorities have driven repeated strategic reversals. The appointment of Hyun Dong-wook, the first CEO with deep multinational medtech commercial credentials, is the most credible leadership choice in years. Investors will reasonably wait for evidence of tenure and a coherent plan.
-
Competitive relevance. The company is strong in Korean hips and cost-competitive in emerging markets. Its R&D base (about 3.6% of sales) and lack of robotics limit its addressable share in the US, where growth expectations are concentrated.
-
Earnings quality. Cash generation in 2025 relied on inventory release. Receivable days remain about 150, and subsidiaries are diluting margins.
Conclusion. On balance the risk/reward has shifted from distressed to value-with-catalysts. A clean H2 2026, meaning OP margins back above 10%, an orderly CB maturity and a first strategic communication from the new CEO, could close part of the discount to book. Further management turnover or a weak H2 would confirm the market's scepticism. Corentec warrants a monitoring position with event-driven triggers rather than a high-conviction call. The single most important variable is not the product portfolio but whether governance stabilises long enough for the export strategy to compound.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Source |
|---|---|---|---|---|
Hyun Dong-wook (현동욱) | CEO and inside director | Since 31 Dec 2025 | Medtronic Asia-Pacific sales and marketing roles and Korea head (1999–2004); Baxter Korea CEO (2004–2008); MSD Korea CEO; Baxter Korea president again from 2018 until resignation in Jul 2022; latterly Teleflex Medical MD; studied biology and biotechnology at the University of California | Dealsite; Etoday/Nate; DailyPharm |
Park Hyung-chul (박형철) | Vice President | Acting CEO 14 Nov – 31 Dec 2025 | — | Edaily; Digital Today |
Kim Jung-sung (김정성) | Vice President | Acting CEO Apr – Jul 2024 | — | Daum/ChosunBiz |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Notes |
|---|---|---|
Sun Doo-hoon (선두훈) | Inside director; founder | Orthopaedic surgeon; chairman of the Younghoon Medical Foundation (Sun Hospital, Daejeon); son-in-law of Hyundai Motor Group honorary chairman Chung Mong-koo (Etoday; Dailymedi) |
Chung Sung-yi (정성이) | Inside director; largest individual shareholder | Advisor at Innocean Worldwide; eldest daughter of Chung Mong-koo; elder sister of Hyundai Motor Group chairman Chung Eui-sun (Investing.com KR 2020; Bloter 2024) |
Sun Seung-hoon, Sun Kyung-hoon | Former co-CEOs (2020 – Mar 2023) | — |
Outside directors | Three attended the 14 Nov 2025 board meeting | — |
Major Shareholders
| Holder | Stake | Date / source |
|---|---|---|
Chung Sung-yi | 7.41% | Q3 2025 (Etoday/Nate, Jan 2026) |
Sun Doo-hoon | 5.47% | Q3 2025 (same) |
Largest shareholder plus related parties (total) | 19.57% | Q3 2025 (same) |
Sun Doo-hoon pledge | 308,642 shares pledged to Shinhan Securities for a KRW 1.5bn loan | 11 Oct 2023 (Dealsite, Feb 2024) |
Sun Seung-hoon and Sun Kyung-hoon pledges | 30,901 shares each for KRW 250M loans each | Dec 2020 (Investing.com KR) |
9th CB holders (original) | Susung Asset Management and others | Dealsite, Oct 2021 |
2016 CB holders (redeemed 2019) | Coston and Premier growth-strategy M&A PEFs | Dealsite, Jul 2019 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | HQ | Relative positioning vs Corentec |
|---|---|---|---|
Hip and knee (global) | Zimmer Biomet | USA | Global No. 1 in recon; FY2025 knee USD 3.3bn and hip USD 2.1bn (Becker's, Feb 2026) |
Hip and knee (global) | Stryker | USA | Orthopaedics USD 9.5bn (FY2025); Mako robotics leader |
Hip and knee (global) | Johnson & Johnson (DePuy Synthes) | USA | — |
Hip and knee (global) | Smith+Nephew | UK | Orthopaedics USD 2.44bn (FY2025); knee about USD 1.0bn and hip USD 641M; CORI robotics |
Hip and knee (China/APAC) | MicroPort Orthopedics / MicroPort Scientific | China | Named as a competitor by PitchBook |
Hip and knee (China) | AK Medical | China | China's largest domestic orthopaedic implant maker per the Yorkshire Evening Post |
Hip and knee (Europe) | Lima Corporate (Enovis), Corin, Exactech | Italy / UK / USA | — |
Korean orthopaedics | Osteonic, Hans Biomed, Huemedix | Korea | Listed as similar companies by TheVC |
Korean spine | L&K Biomed, U&I Corp, Medyssey | Korea | — |
Robotic arthroplasty (Korea) | Curexo (CUVIS-joint) | Korea | Robotics, a capability Corentec lacks |
Peer Comparison FY2025
| Metric (FY2025) | Corentec | Zimmer Biomet | Stryker | Smith+Nephew |
|---|---|---|---|---|
Revenue (USD Mn) | 71.8 | 8,232 | 25,100 | 6,164 |
Reported revenue growth (%) | 7.2 | 7.2 | 11.2 | 6.1 |
Operating margin (%) | 9.0 | — | — | 12.9 |
Net margin (%) | 6.9 | 8.6 | 12.7 | — |
R&D intensity (% of sales) | 3.6 | — | 6.5 | — |



